ZEPBOUND 12.5 mg/.5mL
tirzepatide · INJECTION, SOLUTION · Eli Lilly and Company
No Recall History
Plain English
ZEPBOUND is a injection, solution containing tirzepatide at 12.5 mg/.5mL, taken subcutaneous. Manufactured by Eli Lilly and Company.
Key Facts
- Brand Name
- ZEPBOUND
- Generic Name
- tirzepatide
- NDC Code (Product)
0002-2460- Manufacturer
- Eli Lilly and Company
- Strength
- 12.5 mg/.5mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- SUBCUTANEOUS
- Marketing Status
- Application #
- NDA217806
- Drug Class
- Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]; GLP-1 Receptor Agonist [EPC]
- Marketing Start
- 11/08/2023
Recall History
No Recall HistoryFrequently Asked Questions
What is ZEPBOUND used for?
ZEPBOUND contains tirzepatide. It is a injection, solution taken subcutaneous. Consult your doctor for specific uses.
Is ZEPBOUND a controlled substance?
ZEPBOUND is not classified as a controlled substance by the DEA.
What is the generic name for ZEPBOUND?
The generic name for ZEPBOUND is tirzepatide. There are 10 other brand versions of tirzepatide.
What is the NDC code for ZEPBOUND 12.5 mg/.5mL?
The NDC (National Drug Code) for ZEPBOUND 12.5 mg/.5mL is 0002-2460, listed by Eli Lilly and Company.